



EDAP Reports Conference Success

Clinical Updates Presented From French Luminary Centers, Marketing Programs Attracting Inquiries

LYON, France, Dec. 4, 2006 -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports success in its outreach and marketing efforts at the French Association of Urology (AFU) meeting held recently in Paris.

During this meeting, various scientific communications about Ablatherm HIFU were presented, the largest and only HIFU clinical body at the conference. Among that data were studies detailing efficacy, quality of life preservation, HIFU after radiation failure and potency preservation utilizing the Ablatherm's nerve sparing protocols.

Dr Murat, of Edouard Herriot Hospital, Lyon, and Dr Mallick, of Caen University Hospital, presented results of patients treated with Ablatherm-HIFU after radiotherapy failure in the two main French University centers. The efficacy to safety ratio confirmed the desirability of using Ablatherm and its unique protocols for this patient population. The study also demonstrated the importance of refining the screening criteria in the selection of patients to provide for optimal therapy decisions.

Dr Chevalier, of Pasteur Hospital in Nice, Dr Conort of Pitie Salpetriere in Paris, and Dr Mallick of Caen University Hospital, presented three different approaches of the evaluation of the Quality of Life after Ablatherm- HIFU therapy. Preliminary results of Dr Chevalier's study demonstrated nerve sparing Ablatherm-HIFU therapy could successfully preserve the sexual potency in very selected patients. In the study group, 70% retained potency without the aid of pharmaceuticals while the remaining 30% preserved potency with the use of common pharmaceutical support choices. Dr Conort and Dr Mallick respectively evaluated the consequences of the first and second HIFU sessions with both studies confirming the efficacy of HIFU and the preservation of patients' quality of life as compared to traditional therapy options and outcomes.

EDAP Chief Operating Officer Marc Oczachowski stated, "Once again EDAP was the clear leader in clinical presentations and HIFU participation based on urologist interest from the clinical and technical superiority of Ablatherm- HIFU compared to all other HIFU techniques. With now more than 10 years of experience and 11,000 treatments performed worldwide, EDAP is today providing HIFU therapy to more than 1,000 patients annually in France as the only active HIFU provider in this key global market. EDAP has more than 28 centers offering treatment in France through permanent devices or mobile Ablatherms in rotation among centers."

Additionally, EDAP announced Institut Mutualiste Monsouris, with Pr. Guy Vallancien as the Head of Urology and a long term user of Ablatherm-HIFU, recently acquired a new Ablatherm with the Integrated Imaging system, to share the device on a mobile basis with four additional sites beginning in 2007. The mobilization of another Ablatherm device will allow Ablatherm-HIFU therapy to be available to a larger population at multiple centers and familiarize a greater number of urologists in the best practices of integrating Ablatherm- HIFU into their therapeutic recommendations.

EDAP's dominance in HIFU for localized prostate cancer provided for strong activity at the company information booth as well as strong interest from urologists in learning about HIFU therapy as a part of the therapeutic options available to men seeking to preserve their quality of life. Participants were particularly interested in Ablatherm's ability to provide precise and minimally invasive therapy due to its best-in-class imaging system, the most refined imaging option available in HIFU therapy for localized prostate cancer.

During a successful meeting of the French HIFU Club, gathering all French Ablatherm-HIFU users, active and lively discussions were shared between users about their experience. A detailed review of current medical data was presented together with results obtained using Ablatherm's integrated imaging system allowing the physician to treat and image simultaneously. More than 90% of integrated imaging users report not only greater clarity and visualization, but also improved results due to enhanced accuracy in treatment planning. Based on these outstanding results, most long-term Ablatherm-HIFU French users have upgraded their devices to include the integrated imaging system. Also, given the strong and good results obtained so far using Ablatherm-HIFU, the French Association of Urology decided to submit these recent results to the French Health Authority for a full review in order to accelerate the reimbursement process in France. Finally, during this gathering, Professor Emile Levy of Universite Dauphine in Paris presented an economic analysis of Ablatherm cost compared to external beam radiation and brachytherapy used in localized prostate cancer. In the analysis, HIFU presented as an attractive clinical option based on outcomes and low side effects while a more economical approach in the total cost of care.

EDAP also reports ongoing success in its Lithotripsy business for the French market. France represents an important and dynamic European market where TMS is the clear leader with a high market share. Several communications about the renal lithiasis were presented. Although there were no specific communications about the Sonolith device at the conference, participants discussed the latest publication of Pemberton, Tolley et al in the October 2006 Journal of Endourology. The study demonstrates favorable outcomes obtained with Sonolith Vision compared to other existing lithotripters.

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Halliburton Investor Relations at (972) 458-8000, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at <http://www.edap-tms.com> and <http://www.hifu-planet.com> .